PTC Therapeutics, Inc. $PTCT Shares Acquired by Comerica Bank

Comerica Bank lifted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 3,231.9% during the fourth quarter, Holdings Channel reports. The fund owned 17,426 shares of the biopharmaceutical company’s stock after acquiring an additional 16,903 shares during the period. Comerica Bank’s holdings in PTC Therapeutics were worth $1,324,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WCM Investment Management LLC acquired a new position in shares of PTC Therapeutics during the third quarter worth about $8,919,000. Teachers Retirement System of The State of Kentucky raised its holdings in PTC Therapeutics by 86.9% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 40,858 shares of the biopharmaceutical company’s stock valued at $3,103,000 after acquiring an additional 19,000 shares in the last quarter. Sector Gamma AS raised its holdings in PTC Therapeutics by 28.0% in the third quarter. Sector Gamma AS now owns 118,112 shares of the biopharmaceutical company’s stock valued at $7,249,000 after acquiring an additional 25,862 shares in the last quarter. QRG Capital Management Inc. purchased a new position in PTC Therapeutics in the third quarter worth approximately $2,090,000. Finally, Jefferies Financial Group Inc. purchased a new position in PTC Therapeutics in the third quarter worth approximately $97,252,000.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their price objective on shares of PTC Therapeutics from $81.00 to $82.00 and gave the company a “sector perform” rating in a research report on Friday. TD Cowen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $75.00 to $90.00 in a research report on Friday. Bank of America lowered their target price on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Truist Financial raised PTC Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Barclays restated an “overweight” rating and issued a $120.00 price target on shares of PTC Therapeutics in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $88.36.

Insider Transactions at PTC Therapeutics

In other news, Director Stephanie Okey sold 15,167 shares of PTC Therapeutics stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the sale, the director owned 8,000 shares in the company, valued at approximately $560,000. The trade was a 65.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew B. Klein sold 2,850 shares of the business’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $70.91, for a total value of $202,093.50. Following the completion of the sale, the chief executive officer directly owned 394,070 shares of the company’s stock, valued at $27,943,503.70. The trade was a 0.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 126,492 shares of company stock valued at $8,634,621 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Stock Up 14.3%

Shares of PTC Therapeutics stock opened at $73.69 on Friday. PTC Therapeutics, Inc. has a 52 week low of $43.17 and a 52 week high of $87.50. The firm’s 50 day moving average is $67.69 and its two-hundred day moving average is $72.07. The firm has a market capitalization of $6.11 billion, a P/E ratio of -31.63 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.42. The business had revenue of $272.55 million during the quarter, compared to the consensus estimate of $217.42 million. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The company’s revenue was up 43.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $10.04 EPS. As a group, research analysts expect that PTC Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.